Fluctuations of hepatitis C virus load are not related to amino acid substitutions in hypervariable region 1 and interferon sensitivity determining region

Journal of Medical Virology

Volumn 58, Issue 3, 1999, Pages 247-255

  Hashimoto, Michie ^a,c   Chayama, Kazuaki ^a,b   Kobayashi, Masahiro ^a,b   Tsubota, Akihito ^a,b   Arase, Yasuji ^a,b   Saitoh, Satoshi ^a,b   Suzuki, Yoshiyuki ^a,b   Ikeda, Kenji ^a,b   Matsuda, Marie ^a   Koike, Hiromi ^a   Kobayashi, Mariko ^a   Handa, Hiroshi ^c   Kumada, Hiromitsu ^a,b  

^a TORANOMON HOSPITAL   (Japan)

^b Okinaka Memorial Institute for Medical Research   (Japan)

^c TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

HCV hepatitis; Hypervariable region; Interferon sensitivity determining region; Interferon therapy; Viral titer

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; GENE AMPLIFICATION; GENETIC STABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; SEQUENCE ANALYSIS; VIREMIA; VIRUS LOAD; VIRUS TITRATION;

ALANINE TRANSAMINASE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DNA, VIRAL; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; MOLECULAR SEQUENCE DATA; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY, AMINO ACID; TIME FACTORS; VARIATION (GENETICS); VIRAL ENVELOPE PROTEINS; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS;

EID: 0033001641     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(199907)58:3<247::AID-JMV10>3.0.CO;2-3     Document Type: Article

References (35)

1. Akarca US, Lok AS. 1995. Naturally occurring hepatitis B virus core gene mutations. Hepatology 22:50-60.
2. Asahina Y, Enomoto N, Ogura Y, Kurosaki M, Sakuma I, Izumi N, Marumo F, Sato C. 1996. Sequential changes in full-length genomes of hepatitis B virus accompanying acute exacerbation of chronic hepatitis B. J Hepatol 25:787-794.
3. Chayama K, Saitoh S, Arase Y, Ikeda K, Matsumoto T, Sakai Y, Kobayashi M, Unakami M, Morinaga T, Kumada H. 1991. Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology 3:1040-1043.
4. Chayama K, Tsubota A, Arase Y, Saitoh S, Ikeda K, Matsumoto T, Hashimoto M, Kobayashi M, Kanda M, Morinaga T, Kumada H. 1995. Genotype, slow decrease in virus titer during interferon treatment and high degree of sequence variability of hypervariable region are indicative of poor response to interferon treatment in patients with chronic hepatitis type C. J Hepatol 23:648-653.
5. Chayama K, Tsubota A, Kobayashi M, Okamoto K, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I, Arase Y, Saitoh S, Suzuki Y, Murashima N, Ikeda K, Kumada H. 1997. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic hepatitis C virus infection. Hepatology 25:745-749.
6. Chuang WL, Omata M, Ehata T, Yokosuka O, Ito Y, Imazeki F, Lu SN, Chang WY, Ohto M. 1993. Precore mutations and core clustering mutations in chronic hepatitis B virus infection. Gastroenterology 104:263-271.
7. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer Jr HC, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL. 1989. Treatment of chronic hepatitis C with recombinant interferon alpha. N Engl J Med 321:1501-1506.
8. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH. 1989. Recombinant interferon alpha therapy for chronic hepatitis C. N Engl J Med 321:1506-1511.
9. Dienstag JL. 1983. Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features. Gastroenterology 85:439-462.
10. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, Marumo F, Sato C. 1995. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. J Clin Invest 96:224-230.
11. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. 1996. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334:77-81.
12. Garson JA, Brillanti S, Ring C, Perini P, Miglioli M, Barbara L. 1992. Hepatitis C viraemia rebound after "successful" interferon therapy in patients with chronic non-A, non-B hepatitis. J Med Virol 37: 210-214.
13. Hashimoto M, Chayama K, Tsubota A, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Nakano A, Takagi K, Koike H, Okamoto K, Handa H, Kumada, H. 1996. Typing six major hepatitis C virus genotypes by polymerase chain reaction using primers derived from nucleotide sequence of NS5 region. Int Hepatol Commun 4:263-267
14. Hijikata M, Ohta Y, Baba K, Iwata K, Matsumoto M, Mishiro S, Kanai K:. 1998) Instability of the NS5A ISDR of hepatitis C virus during natural course: take-over of wild type by mutant type or vice-versa driven by immune pressure. Int Hepatol Commun 11:19-25.
15. Hosono S, Tai PC, Wang W, Ambrose M, Hwang DG, Yuan TT, Peng BH, Yang CS, Lee CS, Shih C. 1995. Core antigen mutations of human hepatitis B virus in hepatomas accumulate in MHC class II-restricted T cell epitopes. Virology 212:151-162.
16. Kaneko T, Nakamura I, Kita H0, Hiroishi K, Moriyama T, Imawari M. 1996. Three new cytotoxic T cell epitopes identified within the hepatitis C virus nucleoprotein. J Gen Virol 77:1305-1309.
17. Kao JH, Chen PJ, Lai MY, Wan TH, Chen DS. 1995. Quasispecies of hepatitis C virus and genetic drift of the hypervariable region in chronic type C hepatitis. J Infect Dis 172:261-264.
18. Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Suguyama T, Shimotohno K. 1990. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 87:9524-9528.
19. Kato N, Sekiya H, Ootsuyama Y, Nakazawa T, Hijikata M, Ohkoshi S, Shimotohno, K. 1993. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J Virol 67:3923-3930.
20. Kita H, Hiroishi K, Moriyama T, Okamoto H, Kaneko T, Ohnishi S, Yazaki Y, Imawari, M. 1995. A minimal and optimal cytotoxic T cell epitope within hepatitis C virus nucleoprotein. J Gen Virol 76:3189-3193.
21. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, Huruta S, Akahane Y, Nishioka K, Purcell R, Alte, HJ. 1990. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 67:671-676.
22. Koretz RL, Stone O, Mousa M, Gitnick GL. 1985. Non-A, non-B post-transfusion hepatitis - a decade later. Gastroenterology 88:1251-54.
23. Lee YI, Hur GM, Suh DJ, Kim SH. 1996. Novel pre-C/C gene mutants of hepatitis B virus in chronic active hepatitis: naturally occurring escape mutants. J Gen Virol 77:1129-1138.
24. Li DH, Newbold JE, Cullen JM. 1996. Natural populations of wood-chuck hepatitis virus contain variant precore and core sequences including a premature stop codon in the epsilon motif. Virology 220:256-262.
25. Matsumoto A, Tanaka E, Suzuki T, Ogata H, Kiyosawa K. 1994. Viral and host factors that contribute to efficacy of interferon-α 2a therapy in patients with chronic hepatitis C. Dig Dis Sci 39:1273-1280.
26. Nelson DR, Marousis CG, Davis GL, Rice CM, Wong J, Houghton M, Lau JY. 1997. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 158:1473-1481.
27. Nguyen TT, Sedghi-Vaziri A, Wilkes LB, Mondala T, Pockros PJ, Lindsay KL, McHutchison JG. 1996. Fluctuation in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepat 3:75-78.
28. Polyak SJ, McArdle S, Liu S-L, Sullivan DG, Chung M, Hofgärtner WT, Carithers Jr RL, McMahon BJ, Mullins JI, Corey L, Gretch DR. 1998. Evolution of hepatitis C virus quasispecies in hyper-variable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection. J Virol 72:4288-4296.
29. Rehermann B, Chang KM, McHutchinson J, Kokka R, Houghton M, Rice CM, Chisari FV. 1996. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol 70:7092-7102.
30. Shindo M, Di Bisceglie AM, Hoofnagle JH. 1992. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon. Hepatology 15:1013-1016.
31. Shirai M, Okada H, Nishioka M, Akatsuka T, Wychowski C, Houghten R, Pendleton CD, Feinstone SM, Berzofsky JA. 1994. An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J Virol 68:3334-3342.
32. Tsubota A, Chayama K, Ikeda K, Arase Y, Koida I, Saitoh S, Hashimoto M, Iwasaki S, Kobayashi M, Kumada H. 1994. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 19:1088-1094.
33. Weiner AJ, Brauer MJ, Rosenblatt J, Richman KH, Tung J, Crawford K, Bonino F, Saracco G, Choo QL, Houghton M. 1991. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 180:842-848.
34. Weiner A, Erickson AL, Kansopon J, Crawford K, Muchmore E, Hughes AL, Houghton M, Walker CM. 1995. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci USA 92:2755-2759.
35. Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, Higashi Y, Shibata M, Morishima T. 1992. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-α therapy. Hepatology 16:293-299.